# Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Study · id `cardio:ct-nct05202509` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05202509](<https://clinicaltrials.gov/study/NCT05202509>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05202509

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 9541 participants.

## Technical summary

Registry record NCT05202509. Randomized; quadruple masking; primary purpose treatment. Start 2022-02-07 (actual); primary completion 2026-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 9541 participants (enrolled count; ClinicalTrials.gov record NCT05202509, source copy `cardio:ctgov-nct05202509-2024-06-04`, retrieved 2026-10-31)
- Started: 2022-02-07 (actual) (ClinicalTrials.gov record NCT05202509, source copy `cardio:ctgov-nct05202509-2024-06-04`, retrieved 2026-10-31)
- Primary completion: 2026-11 (anticipated) (ClinicalTrials.gov record NCT05202509, source copy `cardio:ctgov-nct05202509-2024-06-04`, retrieved 2026-10-31)
- Completion: 2026-11 (anticipated) (ClinicalTrials.gov record NCT05202509, source copy `cardio:ctgov-nct05202509-2024-06-04`, retrieved 2026-10-31)
- Countries: United States; Australia; Bulgaria; Canada; China; Croatia; Czechia; Denmark; Finland; Georgia; Germany; Hungary; Israel; Italy; Japan; Jordan; Latvia; Netherlands; Poland; Slovakia; South Africa; Spain; United Kingdom (ClinicalTrials.gov record NCT05202509, source copy `cardio:ctgov-nct05202509-2024-06-04`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05202509-2024-06-04`, retrieved 2026-10-31)

## The registry's words

- Brief title: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
- Acronym: PREVAIL
- Condition: Atherosclerotic Cardiovascular Disease
- Intervention (Drug): Obicetrapib
- Intervention (Drug): Placebo
- Lead sponsor: NewAmsterdam Pharma
- Lead sponsor class: INDUSTRY
- Collaborator: Monash University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: NewAmsterdam Pharma (`cardio:org-newamsterdam-pharma`)
- Registry lists this organization as a collaborator: Monash University (`cardio:org-monash-university`)

## Provenance

Content hash: 85a56884c4c567262b859d97cb8696722593b861434e1228ef5acab7260a518d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
